Hartford Investment Management Co. Has $4.54 Million Stake in Zoetis Inc. (NYSE:ZTS)

Hartford Investment Management Co. decreased its position in Zoetis Inc. (NYSE:ZTS) by 2.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,859 shares of the company’s stock after selling 642 shares during the quarter. Hartford Investment Management Co.’s holdings in Zoetis were worth $4,539,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ZTS. AMF Tjanstepension AB increased its holdings in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after acquiring an additional 20,001 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Zoetis by 4,582.9% during the third quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock worth $320,000 after purchasing an additional 1,604 shares during the period. CX Institutional grew its holdings in Zoetis by 6.3% during the third quarter. CX Institutional now owns 8,142 shares of the company’s stock valued at $1,591,000 after purchasing an additional 482 shares during the last quarter. Creative Planning raised its position in shares of Zoetis by 8.6% in the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after purchasing an additional 7,170 shares during the period. Finally, 626 Financial LLC acquired a new stake in shares of Zoetis in the third quarter worth $212,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.2 %

Shares of NYSE:ZTS opened at $173.99 on Thursday. The company’s fifty day moving average is $169.11 and its 200-day moving average is $179.11. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a market capitalization of $78.50 billion, a PE ratio of 32.70, a P/E/G ratio of 2.77 and a beta of 0.90.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Morgan Stanley dropped their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Piper Sandler reduced their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $214.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.